Jenburkt Pharmaceuticals AGM 2026: Dates, e-voting

What the company announced

Jenburkt Pharmaceuticals Limited has scheduled its 41st Annual General Meeting (AGM) for Friday, September 4, 2026, at 3:30 p.m. IST. The meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM). The company stated the AGM format is aligned with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Alongside the AGM notice, the company disclosed timelines for shareholder voting through remote e-voting. It also reiterated the key dates that determine who can vote and who can receive any dividend declared for FY2025-26.

Key dates: record date, cut-off date, and AGM schedule

Jenburkt fixed Friday, August 28, 2026, as the record date for determining shareholder eligibility for dividend payments for the financial year ended March 31, 2026. The same date also acts as the cut-off date for remote e-voting and e-voting during the AGM.

Shareholders holding shares as of August 28, 2026 are eligible to vote on all resolutions placed before the AGM. The company also said any dividend declared will be disbursed within 30 days following the AGM.

How remote e-voting will work

Members can cast votes using the remote e-voting facility provided by National Securities Depository Limited (NSDL). The e-voting window opens three days before the AGM and closes the day before the meeting.

The company clarified that voting rights will be proportionate to the paid-up value of equity shares held as on the cut-off date. Once a vote is cast through remote e-voting, it cannot be changed. Shareholders who have already voted remotely may still attend the AGM via VC/OAVM, but they cannot vote again.

Members who attend the AGM and have not voted remotely can exercise their voting rights during the AGM or within 15 minutes after the AGM concludes, as stated in the notice.

AGM and e-voting timetable

Annual report dispatch and regulatory reference

The company said its FY2025-26 Annual Report was dispatched electronically on August 3, 2026. The dispatch was stated to be in line with MCA Circular No. 03/2025.

Jenburkt also indicated that its results were filed with the Bombay Stock Exchange under Regulation 34 of SEBI-LODR. These disclosures are relevant for shareholders reviewing the company’s financial statements and AGM resolutions.

FY26 performance: revenue and profit growth

For the financial year ended March 31, 2026 (FY26), Jenburkt reported a year-on-year rise in profitability and revenue. Net profit after tax (PAT) increased 8.34% year-on-year to ₹34.74 crore. Revenue for the year rose 13.02% to ₹168.74 crore.

The company also disclosed earnings per share (EPS) of ₹78.71 for FY26. Statutory auditors D. R. Mehta & Associates issued an unmodified opinion on the financial statements, as per the information provided.

Q1FY27 update: profit declined despite flat revenue

Jenburkt also reported that its Q1FY27 standalone net profit fell 24.45% year-on-year to ₹5.89 crore. The company attributed the decline to increased employee benefit expenses and other costs, even as revenue remained flat.

This quarterly update sits alongside the AGM notice and provides additional context for shareholders assessing operating trends and the cost profile entering FY27.

Dividend proposal: ₹20.70 per share

The Board of Directors recommended a final dividend of ₹20.70 per equity share for FY2025-26. The company described this as a 207% payout on the ₹10 face value.

The dividend is subject to shareholder approval at the 41st AGM. The company also linked the record date of August 28, 2026 to determining which shareholders are entitled to receive the dividend, if approved.

Governance items: CFO and auditor remuneration

Shareholders will also vote on governance-related resolutions at the AGM. The company proposed the reappointment of Dilip H. Bhuta as Whole Time Director and Chief Financial Officer for a five-year term, with the term mentioned as commencing April 1, 2027.

In addition, the AGM agenda includes ratification of the remuneration of the cost auditor, M/s Kirit Mehta & Co. LLP, at ₹0.03 crore plus applicable taxes for FY27 (₹2,75,000 plus taxes).

Snapshot of disclosed financial and agenda items

Market impact and what shareholders will track

The immediate market-relevant takeaway from the notice is procedural but important: shareholders must hold shares as of August 28, 2026 to be eligible to vote and to receive any dividend approved at the AGM. The remote e-voting timetable also gives investors a defined window to participate in the decision-making process.

From a financial perspective, shareholders will evaluate the contrast between FY26 growth in revenue and profit and the Q1FY27 profit decline attributed to higher employee and other costs. The AGM resolutions on dividend approval, reappointment of senior finance leadership, and auditor remuneration together form the core set of decisions for investors to review ahead of September 4.

Conclusion

Jenburkt Pharmaceuticals’ 41st AGM is scheduled for September 4, 2026 via VC/OAVM, with NSDL remote e-voting open from September 1 to September 3 and August 28 as the cut-off and record date. Shareholders will vote on the final dividend of ₹20.70 per share and other resolutions, including key appointments, with dividend payment timelines stated as within 30 days after the AGM if approved.